In this week's #AskDrDurie, the IMF's Dr. Brian Durie answers a very important question regarding the tests available for measuring Minimal Residual Disease. As you may know, the IMF's Black Swan Research Initiative(R) has been evaluating a new flow test method for this, and it is becoming a new benchmark.

Dr. Brian G.M. Durie is the Chairman of the Board of Directors of the International Myeloma Foundation. He began studying multiple myeloma over 30 years ago, and is recognized around the world as one of the top myeloma doctors.

Previous Post
#AskDrDurie: If Pomalyst does not produce a full response, what are my options?
Next Post
#AskDrDurie: Should I have an ASCT if I've been through therapy and am in remission?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.